Trials / Completed
CompletedNCT00141492
Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes
A Double Blind, Randomized, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Androgel, as an Adjunct to Hypoglycemic Therapy, in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- Male
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is to investigate how well Androgel, when tested against placebo gel, helps to control blood sugar levels in males with type 2 diabetes who have low testosterone (the main male hormone) blood levels and are taking oral diabetic medicines alone or in combination with insulin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Androgel (testosterone gel) |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2007-06-01
- Completion
- 2007-06-01
- First posted
- 2005-09-01
- Last updated
- 2015-01-21
Locations
70 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00141492. Inclusion in this directory is not an endorsement.